Healthy
Conditions
Keywords
advantageous inequity, disadvantageous inequity, fMRI, oxytocin
Brief summary
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.
Detailed description
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.
Interventions
DRUGIntranasal oxytocin
Subject assigned to receive intranasal administration of oxytocin (24 IU).
DRUGIntranasal placebo
Subjects assigned to receive intranasal administration of placebo (24 IU).
Sponsors
University of Electronic Science and Technology of China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects without past or current psychiatric or neurological disorders
Exclusion criteria
* history of head injury * pregnant,menstruating,taking oral contraceptives * medical or psychiatric illness. * excessive head movement (\> 3mm) during scanning
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Behavioral index: fairness rating scores | 45-75 minutes after treatment administration | Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair). |
| Behavioral index: preference rating scores | 45-75 minutes after treatment administration | Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable). |
| Neural indices: fMRI-based measures of the outcome presentation stage | 45-75 minutes after treatment administration | Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Behavioral index: choice rate of unequal option | 45-75 minutes after treatment administration | Participants are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose. |
| Neural indices: fMRI-based measures of outcome and re-decision stages | 45-75 minutes after treatment administration | Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose. |
Countries
China
Outcome results
None listed